ESMO 2021: ARCHES Demonstrated Improved Overall Survival With Addition of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer
Enzalutamide also delayed the need for subsequent antineoplastic therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.